Q4 25 EPS
$-0.04
BEAT +22.03%
Est. $-0.05
Q4 25 Revenue
$367.2M
BEAT +1.05%
Est. $363.4M
vs S&P Since Q4 25
-3.9%
TRAILING MARKET
TEM +1.2% vs S&P +5.2%
Full Year 2025 Results
FY 25 EPS
$-0.61
FY 25 Revenue
$1.27B
Market Reaction
Did TEM Beat Earnings? Q4 2025 Results
Tempus AI closed out 2025 with a quarter that Wall Street had been watching closely, reporting Q4 revenue of $367.21 million, an 83% year-over-year surge, while narrowing its adjusted loss to just $0.04 per share, well ahead of the $0.14 analysts had… Read more Tempus AI closed out 2025 with a quarter that Wall Street had been watching closely, reporting Q4 revenue of $367.21 million, an 83% year-over-year surge, while narrowing its adjusted loss to just $0.04 per share, well ahead of the $0.14 analysts had anticipated. The headline driver was a remarkable acceleration in the Diagnostics segment, which posted $266.86 million in Q4 revenue, up 121.6% year-over-year, powered by 29% Oncology volume growth and early momentum in minimal residual disease testing, which hit roughly 4,700 tests in the quarter alone. For the full year, revenue reached $1.27 billion, up 83.4%, while Q4 Adjusted EBITDA turned positive at $12.89 million, a meaningful inflection for a company that has carried substantial losses. Despite a full-year net loss of $245.03 million, management struck a confident tone on the path forward, guiding 2026 revenue to approximately $1.59 billion with Adjusted EBITDA of roughly $65 million, signaling that the company's dual diagnostics and data licensing model is beginning to translate growth into financial discipline.
Key Takeaways
- • Oncology testing volume growth of 29% year-over-year in Q4
- • Hereditary testing volume growth of 23% year-over-year in Q4
- • Insights (data licensing) grew 69.5% in Q4 excluding AstraZeneca warrant impact
- • Ambry Genetics acquisition contributed to inorganic diagnostics growth
- • MRD testing volume up 56% quarter-over-quarter
- • Net Revenue Retention of 126%
TEM YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
TEM Revenue by Segment
With YoY comparisons, source: SEC Filings
“In 2025, Tempus continued to set the standard for what it means to be a technology company operating in the healthcare space. The strength of our unit growth in diagnostics along with the accelerating growth of our data business is proof that we are unique in this space. As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years, but to also enhance the lives of millions of patients around the world.”
— Eric Lefkofsky, Q4 2025 Earnings Press Release
TEM Earnings Trends
TEM vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
TEM EPS Trend
Earnings per share: estimate vs actual
TEM Revenue Trend
Quarterly revenue: estimate vs actual
TEM Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.20 | $-0.13 | +35.36% | $348.1M | +0.78% |
| Q4 25 BEAT FY | $-0.05 | $-0.04 | +22.03% | $367.2M | +1.05% |
| FY Full Year | — | $-0.61 | — | $1.27B | — |
| Q3 25 BEAT | $-0.18 | $-0.11 | +37.25% | $334.2M | +1.68% |
| Q2 25 BEAT | $-0.25 | $-0.25 | +1.15% | $314.6M | +5.67% |
| Q1 25 BEAT | $-0.27 | $-0.24 | +10.21% | $255.7M | +3.07% |